Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756855 | 0.88 | ALDH1A1 (0.53) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL25756934 | 0.88 | ALDH1A1 (0.53) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL6791446 | 0.85 | ALDH1A1 (0.55) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL25756941 | 0.85 | ALDH1A1 (0.42) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL25756864 | 0.83 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1KMT2AMAPT | |
| SCHEMBL2791323 | 0.82 | ALDH1A1 (0.51) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL1407841 | 0.79 | ALDH1A1 (0.43) | ALDH1A1POLBPDE7AMEN1KMT2A | |
| SCHEMBL1921412 | 0.77 | VCAM1 (0.52) | ALDH1A1POLBKCNH2KMT2AMAPT | |
| SCHEMBL12872354 | 0.76 | ALDH1A1 (0.46) | ALDH1A1POLBKCNH2PDE7ACYP19A1 | |
| SCHEMBL13520584 | 0.74 | FFAR1 (0.52) | ALDH1A1KCNH2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2297143-A1 | SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY | Achillion Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110039933-A1 | S1P-1 RECEPTOR AGONISTS | PRAECIS PHARMACEUTICALS INCORPORATION (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039933-A1 | S1P-1 RECEPTOR AGONISTS | PRAECIS PHARMACEUTICALS INCORPORATION (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2164846-A2 | HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS. | Achillion Pharmaceuticals, Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009149436-A1 | SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008147557-A2 | HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | BCAT1, CCNT1, EIF2AK2 | ALDH1A1 1055/4885POLB 921/4885KCNH2 3730/4885 |
| US-20110039933-A1 | S1P-1 RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | ALDH1A1 2195/4885POLB 3370/4885KCNH2 2056/4885 |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | ALDH1A1 474/4885POLB 4019/4885KCNH2 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.